Monopar Therapeutics (MNPR) Accounts Payables (2016 - 2020)

Monopar Therapeutics' Accounts Payables history spans 5 years, with the latest figure at $542068.0 for Q3 2020.

  • For Q3 2020, Accounts Payables rose 12.07% year-over-year to $542068.0; the TTM value through Sep 2020 reached $542068.0, up 12.07%, while the annual FY2019 figure was $724165.0, 81.24% up from the prior year.
  • Accounts Payables for Q3 2020 was $542068.0 at Monopar Therapeutics, up from $525748.0 in the prior quarter.
  • Across five years, Accounts Payables topped out at $724165.0 in Q4 2019 and bottomed at $64510.0 in Q4 2016.
  • The 5-year median for Accounts Payables is $443520.0 (2020), against an average of $420685.1.
  • The largest annual shift saw Accounts Payables soared 383.44% in 2017 before it decreased 23.53% in 2020.
  • A 5-year view of Accounts Payables shows it stood at $64510.0 in 2016, then skyrocketed by 383.44% to $311867.0 in 2017, then increased by 28.12% to $399551.0 in 2018, then surged by 81.24% to $724165.0 in 2019, then decreased by 25.15% to $542068.0 in 2020.
  • Per Business Quant, the three most recent readings for MNPR's Accounts Payables are $542068.0 (Q3 2020), $525748.0 (Q2 2020), and $443520.0 (Q1 2020).